Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.

Journal of pharmaceutics and drug research Pub Date : 2022-01-01 Epub Date: 2022-07-02
Ahizechukwu C Eke
{"title":"Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.","authors":"Ahizechukwu C Eke","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Medication adherence to antiretroviral medications is critical during pregnancy in women living with HIV (WLHIV) for multiple reasons. In this study, we report medication adherence to tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) during pregnancy in WLHIV.</p><p><strong>Methods: </strong>This is a retrospective cohort study of pregnant women living with HIV aged 18-48 years who received either tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) during pregnancy. Medication adherence was assessed during each visit in all trimesters of pregnancy, and was self-reported. Demographics and outcomes were analyzed using standard statistical tests. Logistic regression analysis models accounting for potential confounders, with adjusted odds-ratios (aORs) and associated 95% confidence intervals were reported.</p><p><strong>Results: </strong>One hundred women met inclusion criteria, with thirty-four women on TAF and sixty-six women on TDF. While medication adherence was higher in women using TAF compared to TDF, with 76% adherent to TDF vs 83% adherent to TAF; p=0.282, in the 1<sup>st</sup> trimester; 82% adherent to TDF vs 88% adherent to TAF; p=0.924, in the 2<sup>nd</sup> trimester, and 88% adherent to TDF vs 91% adherent to TAF; p=0.176, in the 3<sup>rd</sup> trimester of pregnancy, these differences in medication adherence were not statistically significant. In the third trimester of pregnancy, multiparous women were more likely to be adherent to TDF/TAF antiretroviral medications compared to nulliparous women - univariable odds ratio, OR 1.31, 95% CI 1.12, 1.57; p<0.05; multivariable (adjusted odds ratio, aOR 1.23, 95% CI 1.08, 1.52; p<0.05).</p><p><strong>Conclusions: </strong>Pregnant women living with HIV on TDF and TAF achieved high adherence, but medication adherence was better in the third trimester compared to the first or second trimesters of pregnancy. These findings support the need to continually assess medication adherence during pregnancy.</p>","PeriodicalId":91912,"journal":{"name":"Journal of pharmaceutics and drug research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281900/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutics and drug research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Medication adherence to antiretroviral medications is critical during pregnancy in women living with HIV (WLHIV) for multiple reasons. In this study, we report medication adherence to tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) during pregnancy in WLHIV.

Methods: This is a retrospective cohort study of pregnant women living with HIV aged 18-48 years who received either tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) during pregnancy. Medication adherence was assessed during each visit in all trimesters of pregnancy, and was self-reported. Demographics and outcomes were analyzed using standard statistical tests. Logistic regression analysis models accounting for potential confounders, with adjusted odds-ratios (aORs) and associated 95% confidence intervals were reported.

Results: One hundred women met inclusion criteria, with thirty-four women on TAF and sixty-six women on TDF. While medication adherence was higher in women using TAF compared to TDF, with 76% adherent to TDF vs 83% adherent to TAF; p=0.282, in the 1st trimester; 82% adherent to TDF vs 88% adherent to TAF; p=0.924, in the 2nd trimester, and 88% adherent to TDF vs 91% adherent to TAF; p=0.176, in the 3rd trimester of pregnancy, these differences in medication adherence were not statistically significant. In the third trimester of pregnancy, multiparous women were more likely to be adherent to TDF/TAF antiretroviral medications compared to nulliparous women - univariable odds ratio, OR 1.31, 95% CI 1.12, 1.57; p<0.05; multivariable (adjusted odds ratio, aOR 1.23, 95% CI 1.08, 1.52; p<0.05).

Conclusions: Pregnant women living with HIV on TDF and TAF achieved high adherence, but medication adherence was better in the third trimester compared to the first or second trimesters of pregnancy. These findings support the need to continually assess medication adherence during pregnancy.

替诺福韦阿拉那胺和富马酸替诺福韦二氯吡酯对HIV感染孕妇依从性的预测。
背景:出于多种原因,艾滋病毒(WLHIV)感染妇女在怀孕期间坚持抗逆转录病毒药物治疗至关重要。在这项研究中,我们报告了妊娠期WLHIV患者对替诺福韦阿拉那胺(TAF)和富马酸替诺福韦二氧吡酯(TDF)的依从性。方法:这是一项回顾性队列研究,年龄在18-48岁的艾滋病毒感染孕妇在怀孕期间接受替诺福韦阿拉那胺(TAF)或富马酸替诺福韦二吡酯(TDF)治疗。在怀孕的所有三个月的每次访问中评估药物依从性,并自我报告。采用标准统计检验对人口统计学和结果进行分析。报告了考虑潜在混杂因素的Logistic回归分析模型,校正优势比(aORs)和相关的95%置信区间。结果:100名妇女符合纳入标准,34名妇女接受TAF治疗,66名妇女接受TDF治疗。与TDF相比,使用TAF的女性的药物依从性更高,76%的人坚持使用TDF,而83%的人坚持使用TAF;P =0.282,在妊娠早期;TDF组82% vs TAF组88%;p=0.924,在妊娠中期,88%的患者坚持TDF, 91%的患者坚持TAF;P =0.176,在妊娠晚期,这些差异在药物依从性上无统计学意义。在妊娠晚期,与未产妇女相比,多产妇女更有可能坚持使用TDF/TAF抗逆转录病毒药物——单变量优势比,OR 1.31, 95% CI 1.12, 1.57;结论:接受TDF和TAF治疗的HIV感染孕妇的依从性较高,但与妊娠早期和中期相比,妊娠晚期的依从性更好。这些发现支持了持续评估怀孕期间药物依从性的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信